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2.  CASE PRESENTATION
A 65-year-old man presented to his primary care 
physician in August 2008 with a 2-month history of 
constipation and occasional right groin pain. His his-
tory was significant for right inguinal hernia repaired 
in 1970. Patient denied any fever, night sweats, vom-
iting, chest pain, abdominal pain, diarrhea, blood in 
stools, or weight loss.
The patient’s history was also significant for 
hypothyroidism, hypertension, gout, type 2 diabetes 
mellitus, hyperlipidemia, and mitral valve disease 
without regurgitation. Current medications included 
lisinopril, insulin, fluoxetine, atorvastatin, thyroxin, 
metformin, and hydrochlorothiazide.
A physical examination was unremarkable. The 
liver and spleen were normal in size. No superficial 
lymphadenopathy was present. Laboratory results 
included hemoglobin 13.3 g/dL and a white cell count 
of 5.5×109/L, with a normal differential. Alanine 
aminotransferase, aspartate aminotransferase, alka-
line phosphatase (a l p ), and lactate dehydrogenase 
(l d h ) were within normal limits. Levels of serum 
alpha-fetoprotein and carcinoembryonic antigen (c e a) 
were not elevated. Serology was negative for h i v  and 
for the hepatitis C (h c v ) and B (h b v ) viruses. Serum 
calcium was within normal limits. In September 2008, 
a c t  scan of abdomen and pelvis showed multiple hy-
podense nodules in the both lobes of the liver, without 
the classical enhancement pattern for hemangioma. 
The pancreas, spleen, and biliary tract were normal 
(Figures 1 and 2). Radiography and c t  scan of chest 
did not reveal any mediastinal lymphadenopathy. 
Magnetic resonance imaging further confirmed the 
c t  findings (Figure 3).
In October 2008, the patient was referred to our 
cancer care centre for further management. Imaging 
by positron-emission tomography was ordered and 
showed hypermetabolic activity (standardized uptake 
value up to 9.8) in a single lesion present in the right 
lobe of the liver.
Histologic analysis after ultrasound-guided 
biopsy of the lesion showed diffuse infiltrates and 
small-to-intermediate atypical cells consistent with 
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1.  INTRODUCTION
Primary hepatic lymphoma (p h l ) is a very rare malig-
nancy 1. Although the liver contains lymphoid tissue, 
host factors may make the liver a poor environment 
for the development of malignant lymphoma 2. We 
present an interesting case of primary non-Hodgkin 
lymphoma (n h l ) originating in liver. A literature re-
view of clinical features, diagnosis, and management 
is also provided.
Written informed consent was obtained from the 
patient for publication of this case report.
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lymphoma (Figure 4). Immunostaining of the tumour 
cells showed reactivity for CD20, CD5, CD45, and 
Bcl6 (Figures 5 and 6).
Bone marrow biopsy showed normal cellularity 
with maturing tri-lineage hematopoiesis in normal 
proportion. No histologic or immunophenotypic 
evidence of B-cell lymphoma was present. Flow 
cytometry showed no phenotypic evidence of n h l . 
Fluorescent in situ hybridization demonstrated no 
evidence of t(11;14), trisomy 11, BCL2 rearrangement, 
or BCL6 breakpoint translocation. Flow cytometry 
and serum protein electrophoresis showed sup-
pressed immunoglobulin M at 47 mg/dL, without 
monoclonal protein.
The patient was diagnosed with primary large 
B-cell lymphoma stage ie of liver, given that no ad-
ditional foci of lymphoma were found anywhere else 
in the body. To date, the patient has received 4 cycles 
of cyclophosphamide–doxorubicin–vincristine–
prednisone/rituximab (c h o p -r) and is planned for total 
of 8 cycles of c h o p -r.
3.  DISCUSSION
Primary hepatic lymphoma is defined as lymphoma 
either confined to the liver or having major liver 
involvement 3. It represents less than 1% of all ex-
tranodal lymphomas 4.
The exact cause of p h l  is unknown, although vi-
ruses such as h b v , h c v , and Epstein–Barr have been 
implicated 3. There appears to be a strong association 
between primary hepatic n h l  and h c v  5. Hepatitis C is 
found in 40%–60% of patients with p h l  4. The possible 
roles of h c v , cirrhosis, and therapeutic interferon in 
lymphomagenesis remain hypothetical 6; however, 
our patient was not positive for h c v  or h b v .
Primary hepatic lymphoma is twice as frequent in 
men as in women, and the usual age at presentation 
f i g u r e  1  Computed tomography scan of abdomen, showing a 
hypodense nodule in the right lobe of the liver.
f i g u r e  2  Computed tomography scan of abdomen, showing multiple 
hypodense nodules in the liver.
f i g u r e  3  Magnetic resonance imaging of the abdomen, showing 
a mass in the right lobe of the liver. No lymphadenopathy or 
splenomegaly is seen.
is 50 years 3. Presentations vary from the incidental 
discovery of hepatic abnormalities in otherwise 
asymptomatic patients (as in our case), to onset of 
fulminant hepatic failure with rapid progression of 
encephalopathy to coma and death 5. Symptoms are 
usually nonspecific, with most patients reporting right 
upper quadrant and epigastric pain, fatigue, weight 
loss, fever, anorexia, and nausea. Hepatomegaly is 
frequent, and jaundice is an occasional finding at 
physical examination 1.
Based on liver infiltration, p h l  can be subdivided 
into nodular or diffuse types 1. The pattern of liver 
infiltration has no prognostic value 4. Similarly, the 
disease may be of either T- or B-cell origin 1. Most p h l  
corresponds to a larger cell type and demonstrates a 
B-cell immunophenotype 6. Other histologic subtypes 
of p h l  include high-grade tumours (lymphoblastic and MASOOD et al.
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Burkett lymphoma, 17%), follicular lymphoma (4%), 
diffuse histiocytic lymphoma (5%), lymphoma of the 
mucosa-associated lymphoid tissue type, anaplastic 
large-cell lymphoma, mantle cell lymphoma, and T-
cell-rich B-cell lymphoma 7.
Patients with p h l typically have abnormal liver 
function tests, with elevation of l d h  and a l p  4. 
Elevated l d h , with normal alpha-fetoprotein and 
c e a , remains a valuable biologic feature 6; but in 
our case, all three markers were negative. For un-
known reasons, hypercalcemia is present in about 
40% of patients 4,7.
On ultrasound, p h l lesions are hypo-echoic 
relative to normal liver. Imaging by c t shows hypo-
attenuating lesions and rim enhancement after con-
trast. Findings on m r i  are variable 8; however, a few 
authors have described hypo-intense T1-weighted 
images and hyper-intense T2-weighted images 9.
Liver biopsy remains the most valuable tool for 
diagnosis of p h l . If a discrete mass is not visible 
on imaging for percutaneous liver biopsy (p l b), the 
transjugular approach may be reasonable. A recent 
review indicated that transjugular liver biopsy can be 
used to obtain adequate tissue samples and that major 
complications and mortality rates are similar to those 
with p l b  3. For p h l  diagnosis, tumour must be confined 
to liver, without involvement of spleen, lymph nodes, 
bone marrow, or other lymphoid structures 7.
Most patients are treated with chemotherapy, with 
some physicians employing a multimodality approach 
that also incorporates surgery and radiotherapy 10. 
The standard treatment for patients with diffuse large 
B-cell lymphoma is c h o p . The addition of rituximab, 
a chimeric mouse–human monoclonal antibody tar-
geting the pan-B-cell antigenic marker CD20 (the 
first monoclonal antibody licensed for use in the 
treatment of cancer 11), to the c h o p  regimen, when 
given in 8 cycles, augments the complete response 
rate and prolongs event-free and overall survival in 
elderly patients with diffuse large B-cell lymphoma, 
without a clinically significant increase in toxicity 12. 
For patients with diffuse large B-cell n h l  (includ-
ing follicular n h l ), several large-scale prospective 
randomized trials have established prolongation of 
remission when rituximab is incorporated into first-
line treatment 13.
Poor prognostic features include advanced age, 
constitutional symptoms, bulky disease, unfavour-
able histologic subtype, elevated levels of l d h  and 
β2-microglobulin, a high proliferation rate, cirrhosis, 
and comorbid conditions 10.
4.  CONCLUSIONS
Primary hepatic lymphoma should be considered 
in the differential diagnosis in a patient with space-
f i g u r e  4	 A	photomicrograph	shows	diffuse	infiltration	by	sheets	
of small-to-intermediate atypical cells. Some cells have evident 
nucleoli.
f i g u r e  6  A photomicrograph shows tumour cells positive for 
CD45.
f i g u r e  5  A photomicrograph shows tumour cells positive for CD20, 
proving B-cell lineage.CASE REPORT: PRIMARY NHL OF LIVER
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occupying liver lesions and normal levels of alpha-
fetoprotein and c e a. Diagnosis of this condition is 
important. If the clinical picture is suspicious for 
p h l , a liver biopsy should be obtained, because the 
disease is treatable, and with new therapeutic drugs 
such as rituximab, overall survival has improved for 
these patients.
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